Subscribe
T. Schneider / Shutterstock.com
21 May 2024NewsBiotechnologyLiz Hockley

USPTO appeals panel cements key claims position in antibody case

ARP maintained rejection of two claims of Xencor’s antibodies patent application | Panel clarified specification for means-plus-function claim limitations.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
USPTO hands win to Daiichi Sankyo in cancer drug dispute
18 January 2024   The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.
Careers
USPTO veteran joins Finnegan as of counsel in Washington, DC
2 May 2024   Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Biotechnology
USPTO hands win to Daiichi Sankyo in cancer drug dispute
18 January 2024   The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.
Careers
USPTO veteran joins Finnegan as of counsel in Washington, DC
2 May 2024   Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades.

More on this story

Biotechnology
USPTO hands win to Daiichi Sankyo in cancer drug dispute
18 January 2024   The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals.
Careers
USPTO veteran joins Finnegan as of counsel in Washington, DC
2 May 2024   Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York